Telix Pharmaceuticals Ltd (TLX)

Sydney
4.760
+0.030(+0.63%)
  • Volume:
    841,699
  • Bid/Ask:
    4.760/4.770
  • Day's Range:
    4.630 - 4.800

TLX Overview

Prev. Close
4.73
Day's Range
4.63-4.8
Revenue
30.19M
Open
4.71
52 wk Range
3.55-8.82
EPS
-0.403
Volume
841,699
Market Cap
1.49B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,469,268
P/E Ratio
-14.97
Beta
2.36
1-Year Change
-19.38%
Shares Outstanding
313,037,968
Next Earnings Date
29 Nov 2022
What is your sentiment on Telix Pharma?
or
Market is currently closed. Voting is open during market hours.

Telix Pharmaceuticals Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Telix Pharmaceuticals Ltd Analysis

Telix Pharmaceuticals Ltd Company Profile

Telix Pharmaceuticals Ltd Company Profile

Employees
0
Market
Australia

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Read More

Analyst Price Target

Average9.242 (+94.16% Upside)
High13.5
Low6.8
Price4.76
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellSell